![تويتر \ OncoKB™ على تويتر: "We just released updated SOPs for OncoKB: https://t.co/vP6IGuZ1zB. Also available now is a mapping between OncoKB and @AMPath / @ASCO / CAP @Pathologists levels of evidence. https://t.co/JOHRLKPsCd" تويتر \ OncoKB™ على تويتر: "We just released updated SOPs for OncoKB: https://t.co/vP6IGuZ1zB. Also available now is a mapping between OncoKB and @AMPath / @ASCO / CAP @Pathologists levels of evidence. https://t.co/JOHRLKPsCd"](https://pbs.twimg.com/media/EVvUPuyWoAMzpru.jpg:large)
تويتر \ OncoKB™ على تويتر: "We just released updated SOPs for OncoKB: https://t.co/vP6IGuZ1zB. Also available now is a mapping between OncoKB and @AMPath / @ASCO / CAP @Pathologists levels of evidence. https://t.co/JOHRLKPsCd"
![Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/ CAP ISH group 4 breast cancer | npj Breast Cancer Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/ CAP ISH group 4 breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-019-0122-x/MediaObjects/41523_2019_122_Fig3_HTML.png)
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/ CAP ISH group 4 breast cancer | npj Breast Cancer
![ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia - ScienceDirect ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0031302518306159-gr1.jpg)
ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia - ScienceDirect
![Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.,JAMA Oncology - X-MOL Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.,JAMA Oncology - X-MOL](https://xpic.x-mol.com/20190315%2F10.1001_jamaoncol.2018.6012.jpg)
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.,JAMA Oncology - X-MOL
![Breast cancer biomarkers, and a new clinical category for HER2 expression | Medical Laboratory Observer Breast cancer biomarkers, and a new clinical category for HER2 expression | Medical Laboratory Observer](https://img.mlo-online.com/files/base/ebm/mlo/image/2022/09/MLO_slides_2.63237b7777324.png?auto=format,compress&fit=fill&fill=blur&w=1200&h=630)
Breast cancer biomarkers, and a new clinical category for HER2 expression | Medical Laboratory Observer
![Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results | Scientific Reports Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-53003-w/MediaObjects/41598_2019_53003_Fig1_HTML.png)
Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results | Scientific Reports
![PDF] HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical PDF] HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical](https://d3i71xaburhd42.cloudfront.net/c7289407931d6ff274350f21b4024900edadc66e/2-Figure1-1.png)